Kangtai
Shenzhen
Vaccine
Kangtai

Recombinant hepatitis B vaccine, Haemophilus influenzae type b conjugate vaccine, Measles and Rubella vaccine, 23 Valent Pneumococcal Polysaccharide Vaccine

Tags:
  • Year Founded: 1992
  • Headquarters: Shenzhen,China
  • Estimated Employees: 1336
  • Product Lines:
  • Products:
    • Acellular DPT vaccine combined with Haemophilus influenzae type B vaccine
    • 23 Valent Pneumococcal Polysaccharide Vaccine
    • Haemophilus influenzae type B acellularis combined vaccine
    • Live attenuated measles rubella vaccine
    • Recombinant hepatitis B vaccine (Saccharomyces cerevisiae)
Kangtai Acellular DPT vaccine combined with Haemophilus influenzae type B vaccine

Kangtai Acellular DPT vaccine combined with Haemophilus influenzae type B vaccine

Shenzhen Kangtai Biological Products Co., Ltd. is a listed enterprise integrating research, development, production and sales of biological products, stock code 300601. Headquartered in Shenzhen, the company has R&D centers and industrial bases in Shenzhen and Beijing. It is one of the major hepatitis B vaccine manufacturers in China.

The company's main business is the development, production and sales of human vaccines. The product categories cover Class I and Class II vaccines. The main products are recombinant hepatitis B vaccine (Saccharomyces cerevisiae), Haemophilus influenzae type b conjugate vaccine, and measles and rubella. Live attenuated vaccine, cell-free white-breaking Haemophilus influenzae type b combined vaccine and other products.

Since its establishment in 1992, Kangtai Bio has undertaken a number of national, provincial and municipal key scientific research projects and technology development tasks. And we have possessed core technologies such as polyvalent vaccines, genetic engineering vaccines and other new technology R&D and industrialization core competitiveness.

The company has 8 research and development carriers such as academician expert workstations. And our products cover more than 3,130 provinces, municipalities and autonomous regions. Among them, the self-developed cell-free whitebait b-type Haemophilus influenzae combined vaccine is the domestically-innovated “quadruple vaccine”. And the 60-microg hepatitis B vaccine specifically targeting unresponsive people has the “National Key New Product” title.

Through more than 20 years of unremitting efforts, Kangtai Bio has become a national-level high-tech enterprise. We have a full range of R&D products, a rich product line, and obvious technological advantages. It has played an important role in the national plan for the immunization front.

In the hepatitis B vaccine alone, Kangtai Bio has produced and sold 1 billion doses. We helped more than 300 million people to rid the hepatitis B virus, and reduced public health expenditure by more than 160 billion yuan.

Relevant Navigation

No comments

You must be logged in to leave a comment!
Login immediately
No comments...